Overview
To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine
Description
A randomized, controlled, and parallel study will comprise 46 patients with UC. Patients will be recruited from GastroEnterology Department, Mansoura University Hospital.
The participants will be randomly assigned into two groups as follow:
Group 1: control group (Mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months.
Group 2: (mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Exclusion Criteria:
- \- Patients with severe UC
- Significant liver and kidney function abnormalities
- Diabetic patients
- Patients with Colorectal cancer patients
- Patients taking rectal or systemic steroids
- Patients on immunosuppressants or biological therapies
- Addiction to alcohol and / or drugs
- Known allergy to the studied medications
- History of complete or partial colectomy.
- Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
- Patients with other inflammatory diseases and active infection.
- Patients with stressful condition (COPD, morbid obesity).
- Patients with liver disease.
- Patients with thrombocytopenia and neutropenia.
- Patients with any type of seizures (case report for mebendazole induced convulsion).
- Patients with renal disease (case report for mebendazole induced nephrotoxicity).
- Patients with coagulation disorders.
- Patients on metronidazole (to avoid Stevens-Johnson syndrome).
- Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
- Patients using antioxidants.
- Pregnant and lactating females.
- Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.
